资讯

Rolling Out3 小时
These two numbers control your entire HIV treatment future
Discover how understanding your viral load and CD4 count puts you in control of HIV treatment and transforms confusing ...
The Pharma Letter8 小时
High costs and limited access threaten progress in HIV treatment despite new drug advances
Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...
Frontiers23 小时
Evolution of antiretroviral therapy: Transitioning from three-drug to two-drug HIV regimens
The field of HIV treatment has witnessed a significant transformation since the mid-1990s with the introduction of combination antiretroviral therapy ...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
Mirage News5 天
FDA Approves Biannual HIV Prevention Injection
Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...
Discover Magazine on MSN11 天
FDA Approves Breakthrough HIV Drug, but It Could Be Hard to Access
Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.
FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.